Attenuation of ischemia-reperfusion injury in a canine model of autologous renal transplantation

Transplantation
Angello LinAvtar Singh

Abstract

This study examined the potential therapeutic effects of a combination therapy consisting of 5-aminoimidazole-4-carboxamide-1-beta-D-ribonucleoside (AICAR) and N-acetyl cysteine (NAC) to attenuate ischemia-reperfusion (I/R) injury in a canine model of autologous renal transplantation. Male mongrel dogs (15-20 kg) underwent left nephrectomy followed by flushing and static preservation of the kidney in University of Wisconsin (UW) solution for 48 hr. The treatment group received AICAR (50 mg/kg) plus NAC (100 mg/kg) intravenously before the left nephrectomy. The compounds were added to the UW solution as well. All dogs underwent right nephrectomy 48 hr later followed by autotransplantation of the preserved left kidney. Treated dogs received a second dose of AICAR and NAC before implantation of the renal autograft. The treated dogs had excellent urine output posttransplant, with peak serum creatinine of 7.26 mg/dL on postoperative day (POD) 3 that normalized after 14 days. The control group were anuric and developed clinical symptoms of uremia on POD 1. Morphologic evaluation supported the protective effects of combination therapy. Immunohistochemical analysis revealed decrease of tumor necrosis factor-alpha, interferon-gamma, and...Continue Reading

References

Apr 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·N B VedderJ M Harlan
Jan 1, 1994·Advances in Experimental Medicine and Biology·T PageW L Nyhan
Apr 1, 1995·British Heart Journal·A M Alkhulaifi, W B Pugsley
Mar 1, 1995·The Journal of Thoracic and Cardiovascular Surgery·J P MathewB R Smith
Jul 20, 2000·The New England Journal of Medicine·M TepelW Zidek
Dec 4, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·C PeraltaJ Roselló-Catafau
Apr 15, 2003·Brain Research·Bipanjeet SekhonAvtar K Singh

❮ Previous
Next ❯

Citations

Nov 27, 2007·Naunyn-Schmiedeberg's Archives of Pharmacology·Prabal K Chatterjee
Jul 18, 2012·Current Opinion in Nephrology and Hypertension·Núria M Pastor-Soler, Kenneth R Hallows
Feb 26, 2010·American Journal of Physiology. Renal Physiology·Kenneth R HallowsDavid A Power
Aug 19, 2011·American Journal of Physiology. Renal Physiology·Patricia W Seo-MayerMichael J Caplan
Jan 7, 2014·Néphrologie & thérapeutique·Pauline ErpicumFrançois Jouret
Feb 14, 2012·British Journal of Pharmacology·J LempiäinenE Mervaala
Nov 3, 2010·Transplant Immunology·Federico CicoraClemente Raimondi
Jun 23, 2011·Transplantation Proceedings·A DanilovicA C Seguro
Sep 13, 2014·The Journal of Surgical Research·Adam KhaderPing Wang
Feb 26, 2016·Antioxidants & Redox Signaling·Brian B RatliffMichael S Wolin
Oct 24, 2013·Current Opinion in Critical Care·Samir M Parikh
Apr 28, 2020·Expert Opinion on Therapeutic Targets·Sandra Rayego-Mateos, Jose M Valdivielso
May 18, 2021·American Journal of Physiology. Renal Physiology·Sorena LoNirmala Parajuli
May 21, 2008·Asian Journal of Surgery·Erman AytacHakki Oktay Seymen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis